Comparing Prognosis Associated with Partial Cystectomy and Trimodal Therapy for Muscle-Invasive Bladder Cancer Patients

被引:3
|
作者
Su, Quanxin [1 ,2 ]
Gao, Shenglin [1 ]
Lu, Chao [1 ]
Wu, Xingyu [1 ]
Zuo, Li [1 ]
Zhang, Lifeng [1 ]
机构
[1] Nanjing Med Univ, Dept Urol, Affiliated Changzhou Peoples Hosp 2, Changzhou, Peoples R China
[2] Dalian Med Univ, Dept Grad Sch, Dalian, Peoples R China
关键词
Muscle-invasive bladder cancer; Bladder-sparing therapy; Prognosis; Propensity score model; LONG-TERM OUTCOMES; RADICAL CYSTECTOMY; UROTHELIAL CARCINOMA; NEOADJUVANT CHEMOTHERAPY; MANAGEMENT; PRESERVATION;
D O I
10.1159/000518562
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: This study aimed to compare the survival outcomes between trimodal therapy (TT) and partial cystectomy (PC) in muscle-invasive bladder cancer (MIBC) patients. Methods: The data of 13,096 patients with MIBC diagnosed between 2004 and 2015 were retrieved from the Surveillance, Epidemiology, and End Results database. Among them, 4,041 patients underwent TT and 1,670 patients underwent PC. Propensity score matching was performed to balance the characteristics between the 2 treatment groups. A multivariate Cox regression analysis model and a competing risk model were used to evaluate overall survival (OS) and cancer-specific survival. Cumulative incidence survival curves were obtained using the Kaplan-Meier method. Results: Results of multivariate Cox analysis before propensity score matching showed that the TT group had a 31% reduction in cause-specific survival relative to the PC group (HR: 0.69, 95% CI: 0.61-0.78, p < 0.001) and a 28% reduction in OS (HR: 0.72, 95% CI: 0.66-0.79, p < 0.001). After propensity score matching, the 2 groups yielded 972 patients, with 3-year cause-specific survival rates of 54.1% and 68.5% in the TT group and the PC group, respectively. Conclusions: Patients who underwent PC had a better prognosis than those who received TT. In addition, for MIBC patients who required bladder-sparing therapy, advanced age (>= 80 years), pathological type of squamous cell carcinoma, and tumor stage of T3-4, N2-3, and M1 were independent poor prognostic factors.
引用
收藏
页码:46 / 57
页数:12
相关论文
共 50 条
  • [1] Comparison of radical cystectomy with trimodal therapy in muscle-invasive bladder cancer
    Fleischmann, M.
    Roedel, C.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2023, 199 (09) : 871 - 873
  • [2] Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer
    Williams, Stephen B.
    Shan, Yong
    Jazzar, Usama
    Mehta, Hemalkumar B.
    Baillargeon, Jacques G.
    Huo, Jinhai
    Senagore, Anthony J.
    Orihuela, Eduardo
    Tyler, Douglas S.
    Swanson, Todd A.
    Kamat, Ashish M.
    JAMA SURGERY, 2018, 153 (10) : 881 - 889
  • [3] Comparing trimodal therapy with radical cystectomy in muscle-invasive bladder cancer: an updated meta-analysis
    Al-Qudimat, Ahmad R.
    Singh, Kalpana
    Ojha, Laxmi K.
    Moustafa, Diala Alhaj
    Elaarag, Mai
    Al-Zoubi, Raed M.
    Aboumarzouk, Omar M.
    FRONTIERS IN SURGERY, 2023, 10
  • [4] Comparing costs of radical cystectomy versus trimodal therapy for patients diagnosed with localized muscle-invasive bladder cancer.
    Ray-Zack, Mohamed Danny
    Shan, Yong
    Kerr, Preston
    Kosarek, Christopher David
    Hudgins, Hogan K.
    Jazzar, Usama
    Tyler, Douglas S.
    Freedland, Stephen J.
    Swanson, Todd A.
    Baillargeon, Jacques G.
    Hu, Jim C.
    Kaul, Sapna
    Kamat, Ashish M.
    Gore, John L.
    Mehta, Hemalkumar B.
    Williams, Stephen Bentley
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Comparing costs of radical cystectomy versus trimodal therapy for patients diagnosed with localized muscle-invasive bladder cancer.
    Phillips, Daniel
    Dafashy, Tamer
    Shan, Yong
    Ray-Zack, Mohamed Danny
    Hudgins, Hogan K.
    Jazzar, Usama
    Tyler, Douglas S.
    Freedland, Stephen J.
    Swanson, Todd A.
    Baillargeon, Jacques G.
    Hu, Jim C.
    Kaul, Sapna
    Kamat, Ashish M.
    Gore, John L.
    Mehta, Hemalkumar B.
    Williams, Stephen Bentley
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Trimodal therapy for muscle-invasive bladder cancer
    Mathes, Joachim
    Rausch, Steffen
    Todenhoefer, Tilman
    Stenzl, Arnulf
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (12) : 1219 - 1229
  • [7] Re: Comparing Survival Outcomes and Costs Associated with Radical Cystectomy and Trimodal Therapy for Older Adults with Muscle-Invasive Bladder Cancer
    Griebling, Tomas L.
    JOURNAL OF UROLOGY, 2019, 201 (05): : 837 - 837
  • [8] Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in Muscle-Invasive Bladder Cancer
    Kumar, A.
    Cherry, D. R.
    Deka, R.
    Nalawade, V.
    Efstathiou, J. A.
    Stewart, T. F.
    Rose, B. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E873 - E874
  • [9] Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans
    Kumar, Abhishek
    Cherry, Daniel R.
    Courtney, Patrick T.
    Nalawade, Vinit
    Kotha, Nikhil
    Riviere, Paul J.
    Efstathiou, Jason
    McKay, Rana R.
    Kader, A. Karim
    Rose, Brent S.
    Stewart, Tyler F.
    EUROPEAN UROLOGY OPEN SCIENCE, 2021, 30 : 1 - 10
  • [10] Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer
    Williams, Stephen B.
    Shan, Yong
    Ray-Zack, Mohamed D.
    Hudgins, Hogan K.
    Jazzar, Usama
    Tyler, Douglas S.
    Freedland, Stephen J.
    Swanson, Todd A.
    Baillargeon, Jacques G.
    Hu, Jim C.
    Kaul, Sapna
    Kamat, Ashish M.
    Gore, John L.
    Mehta, Hemalkumar B.
    JAMA SURGERY, 2019, 154 (08)